Brief: Immunovant Announces Proposed Offering Of $300 Million Of Common Stock
Immunovant announces $300 mln equity offering after stock doubles
US STOCKS-Wall St pounded as investors grapple with higher rates
US STOCKS-Wall St pounded as investors grapple with higher rates
US STOCKS-Wall St slides over 1% as Treasury yields hover at 16-year peaks
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
Immunovant surges as antibody treatment succeeds in early-stage study
U.S. STOCKS ON THE MOVE-BullFrog AI, Soleno,
Immunovant shares surge after antibody treatment succeeds in early-stage study (updated)
U.S. STOCKS ON THE MOVE-DraftKings, Immunovant
Immunovant shares surge after antibody treatment succeeds in early-stage study
Immunovant jumps after antibody treatment shows promise in study
Brief: Immunovant Inc Announces Positive Initial IMVT-1402 Phase 1 SAD And 300 Mg Subcutaneous MAD Results
Immunovant Inc reports results for the quarter ended in June - Earnings Summary
Immunovant Inc expected to post a loss of 45 cents a share - Earnings Preview
Immunovant up as rival Argenx's neurological disorder drug meets main goal
U.S. RESEARCH ROUNDUP-Cleveland-Cliffs, Graftech International, Steel Dynamics
Brief: Immunovant Provides Corporate Updates And Reports Q4 And Fiscal Year Ended March 31, 2023 Financial Results
Big pharma interest in immunology sector to grow in near to medium term - Jefferies